Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Accumulated Expenses (2017 - 2026)

Cogent Biosciences' Accumulated Expenses history spans 10 years, with the latest figure at $6.2 million for Q1 2026.

  • Quarterly Accumulated Expenses rose 69.18% to $6.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $6.2 million through Mar 2026, up 69.18% year-over-year, with the annual reading at $52.9 million for FY2025, 25.56% up from the prior year.
  • Accumulated Expenses came in at $6.2 million for Q1 2026, down from $52.9 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $52.9 million in Q4 2025 to a low of $2.2 million in Q1 2023.
  • The 5-year median for Accumulated Expenses is $12.0 million (2022), against an average of $17.4 million.
  • Year-over-year, Accumulated Expenses surged 805.24% in 2024 and then plummeted 81.38% in 2025.
  • Cogent Biosciences' Accumulated Expenses stood at $17.9 million in 2022, then surged by 46.09% to $26.1 million in 2023, then surged by 61.26% to $42.1 million in 2024, then increased by 25.56% to $52.9 million in 2025, then tumbled by 88.27% to $6.2 million in 2026.
  • Per Business Quant, the three most recent readings for COGT's Accumulated Expenses are $6.2 million (Q1 2026), $52.9 million (Q4 2025), and $44.5 million (Q3 2025).